Lambermont M, Servais C, Andrien M, Dupont E
Département d'Immunologie, Hématologie, Transfusion, Hôpital Erasme, Bruxelles.
Rev Med Brux. 1992 Apr;13(4):117-23.
Neonatal alloimmune thrombocytopenia (NAIT) is due to fetomaternal incompatibility for platelet specific antigens, most frequently HPA-1a (PLA1) and HPA-5b (BRa). It occurs in approximately 1/2.000-1/5.000 births. The most serious complication of NAIT is intracranial hemorrhage. The risk of life-threatening hemorrhage must lead to prompt diagnosis and effective therapy. Improvements in antenatal diagnosis and in utero therapy facilitate appropriate management of pregnancy at risk for NAIT. We report our experience with the serological diagnosis of 14 NAIT cases using new performing techniques such as western blotting (WB) and MAIPA (monoclonal antibody specific immobilization of platelet antigens).
新生儿同种免疫性血小板减少症（NAIT）是由于胎儿与母亲之间血小板特异性抗原不相容所致，最常见的是HPA-1a（PLA1）和HPA-5b（BRa）。其发生率约为1/2000 - 1/5000活产儿。NAIT最严重的并发症是颅内出血。危及生命的出血风险必须促使进行快速诊断和有效治疗。产前诊断和宫内治疗的进展有助于对有NAIT风险的妊娠进行适当管理。我们报告了使用诸如蛋白质印迹法（WB）和单克隆抗体特异性血小板抗原固定法（MAIPA）等新的检测技术对14例NAIT病例进行血清学诊断的经验。
